Hypoxia-inducible factor 2α: A novel target in gliomas

Jaclyn J. Renfrow, Michael H. Soike, Waldemar Debinski, Shakti H. Ramkissoon, Ryan T. Mott, Mark B. Frenkel, Jann N Sarkaria, Glenn J. Lesser, Roy E. Strowd

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Hypoxia is an important contributor to aggressive behavior and resistance mechanisms in glioblastoma. Upregulation of hypoxia inducible transcription factors (HIFs) is the primary adaptive cellular response to a hypoxic environment. While HIF1α has been widely studied in cancer, HIF2α offers a potentially more specific and appealing target in glioblastoma given expression in glioma stem cells and not normal neural progenitors, activation in states of chronic hypoxia and expression that correlates with glioma patient survival. A first-in-class HIF2α inhibitor, PT2385, is in clinical trials for renal cell carcinoma, and provides the first opportunity to therapeutically target this important pathway in glioma biology.

Original languageEnglish (US)
Pages (from-to)2227-2236
Number of pages10
JournalFuture Medicinal Chemistry
Volume10
Issue number18
DOIs
StatePublished - Sep 1 2018

Keywords

  • cancer
  • glioblastoma
  • hypoxia
  • hypoxia-inducible factors

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'Hypoxia-inducible factor 2α: A novel target in gliomas'. Together they form a unique fingerprint.

  • Cite this

    Renfrow, J. J., Soike, M. H., Debinski, W., Ramkissoon, S. H., Mott, R. T., Frenkel, M. B., Sarkaria, J. N., Lesser, G. J., & Strowd, R. E. (2018). Hypoxia-inducible factor 2α: A novel target in gliomas. Future Medicinal Chemistry, 10(18), 2227-2236. https://doi.org/10.4155/fmc-2018-0163